ROLE OF MAGNESIUM PREPARATIONS IN IMPROVING THE OUTCOMES OF PRIMIPREGNANCY

Objective. To evaluate the efficiency of replenishing magnesium deficiency to prevent gestational complications and to improve primipregnancy outcomes. Subject and methods. A prospective clinical (standard procedures), and laboratory (biochemical screening) study was conducted in 100 primigravidae at 11-12 and 16-18 weeks’ gestation who were divided into 2 groups: 1) 50 pregnant women who had received magne B6 forte since their registration (a study group) and 2) 50 who had not during pregnancy (a control group). The plasma levels of human chorionic gonadotropin, pregnancy-associated plasma protein A, magnesium, and alpha-fetoprotein were determined. Results. The primigravidae receiving magne B6 forte to replenish magnesium deficiency and to prevent gestational complications exhibited improved biochemical parameters, lower rates of fetoplacental insufficiency, fetal growth retardation, threatened miscarriage, gestational anemia, and significantly better pregnancy outcomes. Conclusion. The administration of easily digestible organic magnesium salts (magnesium citrate) in combination with pyridoxine makes it possible to optimize the course of gestational processes, to achieve the optimal level of cell metabolism, and to promote the favorable outcome of primipregnancy.

primipregnancy, gestational complications, magnesium deficiency, magnesium citrate, pyridoxine